Safety Considerations As with any compounded sterile injectable, prescribers should screen patients before administration: G6PD deficiency: Patients with known or suspected G6PD deficiency should be evaluated carefully, as IV glutathione and related sulfhydryl compounds have been associated with hemolysis in this population
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which means it mimics the action of a naturally occurring hormone called GLP-1
Improved Metabolic Flexibility and Resilience: One of the most exciting metabolic effects of Retatrutide is its potential to restore metabolic flexibilitythe body's ability to switch effectively between using carbohydrates and fats as fuel
Quality Standards InjectCo incorporates compounded medications sourced from a licensed 503B pharmacy as part of its weight loss program
Semaglutide is FDA approved and widely prescribed when appropriate
Before beginning any large-scale study, a patch test is essential to rule out sensitivity or irritation, particularly from the azelaic acid